Back to top
more

JanOne Inc. (JAN)

(Delayed Data from NSDQ)

$9.46 USD

9.46
296,739

+0.41 (4.53%)

Updated Apr 9, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.93%
2Buy18.55%
3Hold10.24%
4Sell5.98%
5Strong Sell2.69%
S&P50011.00%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (165 out of 254)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

JanOne is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, which are undergoing review to determine appropriate strategic alternatives.

General Information

JanOne Inc.

325 E. Warm Springs Road Suite 102

Las Vegas, NV 89119

Phone: 702-997-5968

Fax: 952-930-1800

Web: http://www.janone.com

Email: ir@janone.com

Industry Medical - Drugs
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2021
Next EPS Date NA

EPS Information

Current Quarter EPS Consensus Estimate NA
Current Year EPS Consensus Estimate NA
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date NA

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 9.05
52 Week High 12.99
52 Week Low 2.23
Beta 1.83
20 Day Moving Average 426,625.31
Target Price Consensus 0.00

JAN

% Price Change
4 Week 7.38
12 Week 72.94
YTD 93.46
% Price Change Relative to S&P 500
4 Week 2.45
12 Week 58.98
YTD 69.66
Share Information
Shares Outstanding (millions) 2.40
Market Capitalization (millions) 22.74
Short Ratio NA
Last Split Date 4/22/2019
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year 61.61%
vs. Previous Quarter 64.75%
   
Sales Growth
vs. Previous Year -19.88%
vs. Previous Quarter -25.45%
   
Price Ratios
Price/Book 7.32
Price/Cash Flow NA
Price / Sales 0.67
ROE
3/31/21 NA
12/31/20 -153.26
9/30/20 -161.07
ROA
3/31/21 NA
12/31/20 -33.09
9/30/20 -45.22
Current Ratio
3/31/21 NA
12/31/20 0.34
9/30/20 0.41
Quick Ratio
3/31/21 NA
12/31/20 0.26
9/30/20 0.36
Operating Margin
3/31/21 NA
12/31/20 -25.09
9/30/20 -33.60
Net Margin
3/31/21 NA
12/31/20 -25.09
9/30/20 -33.60
Pre-Tax Margin
3/31/21 NA
12/31/20 -26.35
9/30/20 -38.64
Book Value
3/31/21 NA
12/31/20 1.29
9/30/20 2.88
Inventory Turnover
3/31/21 NA
12/31/20 17.14
9/30/20 19.92
Debt-to-Equity
3/31/21 NA
12/31/20 0.00
9/30/20 0.00
Debt to Capital
3/31/21 NA
12/31/20 0.00
9/30/20 0.00